Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.
The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as the first line of treatment for decreasing LDL levels in the body, it exhibits secondary effects, such as hepatic enzyme elevation or muscular pain in some patients. Moreover, statins do not decrease the risk of cardiovascular diseases completely and is not recommended for patients having diabetes. This has encouraged researchers to focus on the evaluation of new drug targets, including triglyceride-rich particle metabolism regulators, proteins involved in glycoprotein recognition and clearance, and inflammatory pathways that affect efferocytosis. For instance, new proatherosclerotic pathways, such as lipoprotein A (LPA) and PCSK9 can significantly minimize the risk of atherosclerosis. PCSK9 inhibitors exhibit high therapeutic efficacy in reducing atherogenesis and do not increase the incidence of type 2 diabetes. Although more clinical trials are required for their use among atherosclerosis patients, continuous R&D in this field will positively impact the growth of the atherosclerosis therapeutics market.
Market Analysis and Insights: Global Atherosclerosis Therapeutics Market
In 2019, the global Atherosclerosis Therapeutics market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.
Global Atherosclerosis Therapeutics Scope and Market Size
Atherosclerosis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Atherosclerosis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Atherosclerosis Therapeutics market is segmented into Small Molecules, Biologics, etc.
Segment by Application, the Atherosclerosis Therapeutics market is segmented into Hospital, Clinic, Research Institute, Other, etc.
Regional and Country-level Analysis
The Atherosclerosis Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Atherosclerosis Therapeutics market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Atherosclerosis Therapeutics Market Share Analysis
Atherosclerosis Therapeutics market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Atherosclerosis Therapeutics business, the date to enter into the Atherosclerosis Therapeutics market, Atherosclerosis Therapeutics product introduction, recent developments, etc.
The major vendors include AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi, etc.

This report focuses on the global Atherosclerosis Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Atherosclerosis Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

AstraZeneca Plc
Bayer AG
Merck & Co. Inc.
Novartis AG
Sanofi
...

Market segment by Type, the product can be split into

Small Molecules
Biologics

Market segment by Application, split into

Hospital
Clinic
Research Institute
Other

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Atherosclerosis Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Atherosclerosis Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Atherosclerosis Therapeutics are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.